Ms. Staib is Director and Partner of William Hood & Company, a differentiated industry-focused investment banking firm covering the Consumer, Food and Retail sectors with a specialization in health and wellness.
Prior to William Hood & Company, Jill was Vice President of Strategic Initiatives for The Nature’s Bounty Company, the largest pure-play manufacturer and marketer of health and wellness products in the world with over $3 billion in annual revenue. Her global role focused on M&A, Corporate Development and Growth Strategy. In this capacity, she led a variety of global projects for the company including the sale of The Nature’s Bounty Co. from The Carlyle Group to KKR and the sale of U.K. based retailer Holland & Barrett from The Carlyle Group to Letter1 Retail. Jill was also involved in the acquisitions of natural personal care brand Dr. Organic, leading bar brand Best Bar Ever, as well as in the company’s joint venture with By-Health in China.
During her tenure at The Nature’s Bounty Co., Jill also held a variety of operating leadership roles including managing the Nature’s Bounty, Pure Protein, Body Fortress and Met-Rx brands, as well as the company’s Private Label business. Jill’s passion for brands combined with her retailer relationships resulted in her driving a number of the key strategic growth initiatives behind the success of the company leading up to its sale. While managing the Nature’s Bounty brand, Jill successfully created and launched the Optimal Solutions line including its flagship Hair, Skin and Nails product, the current market leader in women’s health supplements and the fastest growing line extension in the company’s history with over $100M in revenue. She was also responsible for the turn-around of Pure Protein, a leading mass market brand in the Active Nutrition category.
Prior to joining The Nature’s Bounty Co., Jill was the Brand Director for natural skincare line Naturopathica Holistic Health. In that role Jill was responsible for product design, marketing and distribution.
Ms. Staib holds the following FINRA Registrations: Series 79